Can a Three-Drug cocktail shrink stomach tumors before surgery?
NCT ID NCT06447636
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This phase 2 trial is testing whether adding surufatinib (a targeted therapy that blocks blood vessel growth) to standard immunotherapy and chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment is given before and after surgery to shrink the tumor and increase the chance of complete removal. The study will measure how many patients have no cancer cells left in the removed tissue (pathological complete response) and how long they remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of surufatinib (a kinase inhibitor), sintilimab (an immunotherapy), and chemotherapy (oxaliplatin and S1)
- What this could lead to
- If successful, this approach could improve tumor shrinkage before surgery and increase the chance of complete removal, potentially leading to better long-term survival for people with locally advanced gastric cancer.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination of drugs may cause significant side effects, and it is not yet known whether it will improve outcomes compared to standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Cancer Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a less extensive stomach surgery preserve appetite better?
- Can a vaccine stop stomach cancer from coming back?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Breath of life: new test could sniff out gut cancers before they spread